Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer - Reply

被引：0
|
作者：
Dawson, NA [1 ]
机构：
[1] Walter Reed Army Med Ctr, Washington, DC 20307 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1999年 / 17卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1646 / 1646
页数：1
相关论文
共 50 条
  • [1] Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer
    Schmid, HP
    Semjonow, A
    Maibach, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1645 - 1646
  • [2] Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
    Semeniuk, Ross C.
    Venner, Peter M.
    North, Scott
    [J]. UROLOGY, 2006, 68 (03) : 565 - 569
  • [3] Economic impact of prostate-specific antigen doubling time in patients with hormone-refractory prostate cancer
    Mulani, P
    Botteman, M
    Hay, JW
    Cifaldi, M
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 346 - 346
  • [4] Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen
    Tomioka, Susumu
    Shimbo, Masashi
    Amiya, Yoshiyasu
    Nakatsu, Hiroomi
    Murakami, Shino
    Shimazaki, Jun
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) : 36 - 42
  • [5] The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer
    Smith, DC
    Pienta, KJ
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) : 433 - &
  • [6] Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
    Oudard, S.
    Banu, E.
    Scotte, F.
    Banu, A.
    Medioni, J.
    Beuzeboc, P.
    Joly, F.
    Ferrero, J. -M.
    Goldwasser, F.
    Andrieu, J. -M.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (11) : 1828 - 1833
  • [7] Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
    Sartor, O
    Weinberger, M
    Moore, A
    Li, AL
    Figg, WD
    [J]. UROLOGY, 1998, 52 (02) : 252 - 256
  • [8] Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)
    Armstrong, A. J.
    Eisenberger, M. A.
    Garrett-Mayer, E. S.
    Yang, Y. Ou
    Carducci, M. A.
    de Wit, R.
    Tannock, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] EVALUATION OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE MARKER FOR RESPONSE OF HORMONE-REFRACTORY PROSTATE-CANCER TO SURAMIN THERAPY
    SRIDHARA, R
    EISENBERGER, MA
    SINIBALDI, VJ
    REYNO, LM
    EGORIN, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) : 2944 - 2953
  • [10] Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer
    Newling, Don W. W.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (01) : 13 - 19
12345